Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Living in context with the survival factor BAFF.

Literature DB >> 18342003

Living in context with the survival factor BAFF.

Abstract

In this issue, Gardham et al. (2008) show that BAFF, a tumor necrosis factor (TNF) family member, promotes B cell survival by hindering interactions between TNF-receptor-associated factors, blocking their negative regulation of nonclassical NF-kappaB activity.

Entities: Gene

Mesh：

Substances：

Year: 2008 PMID： 18342003 DOI： 10.1016/j.immuni.2008.02.010

Source DB: PubMed Journal: Immunity ISSN： 1074-7613 Impact factor: 31.745

Keyword Cloud
Cited

6 in total

1. B cell phenotypes in patients with rheumatoid arthritis relapsing after rituximab: expression of B cell-activating factor-binding receptors on B cell subsets.

Authors: E Becerra; I De La Torre; M J Leandro; G Cambridge
Journal: Clin Exp Immunol Date: 2017-09-25 Impact factor: 4.330

2. Constitutive BR3 receptor signaling in diffuse, large B-cell lymphomas stabilizes nuclear factor-κB-inducing kinase while activating both canonical and alternative nuclear factor-κB pathways.

Authors: Lan V Pham; Lingchen Fu; Archito T Tamayo; Carlos Bueso-Ramos; Elias Drakos; Francisco Vega; L Jeffrey Medeiros; Richard J Ford
Journal: Blood Date: 2010-10-01 Impact factor: 22.113

Living in context with the survival factor BAFF.

1. B cell phenotypes in patients with rheumatoid arthritis relapsing after rituximab: expression of B cell-activating factor-binding receptors on B cell subsets.

2. Constitutive BR3 receptor signaling in diffuse, large B-cell lymphomas stabilizes nuclear factor-κB-inducing kinase while activating both canonical and alternative nuclear factor-κB pathways.

3. TNF receptor-associated factor 3 is required for T cell-mediated immunity and TCR/CD28 signaling.

Review 4. B cells and transplantation: an educational resource.

5. The design and characterization of receptor-selective APRIL variants.

6. Autoantibodies against BAFF, APRIL or IL21 - an alternative pathogenesis for antibody-deficiencies?